Concepedia

Sayeh Tadayon

ST

Statistics

Publications

5

Citations

1.8K

H-Index

5

Active since

2019

Affiliations

Novo Nordisk (Denmark)(Current)

University of Leicester

Dallas Diabetes Research Center

Sayeh Tadayon is an author at Novo Nordisk (Denmark) specializing in clinical pharmacology, pharmacotherapy, and diabetes management.

Publications per year

2019–2021

5

Publications

5

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

Domenica Rubino, Niclas Abrahamsson, Melanie J. Davies et al. · JAMA · 2021 · 1.2K citations · Full text

, , +17

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon et al. · Diabetes Obesity and Metabolism · 2020 · 384 citations · Full text

, , +17

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials

Johannes F.E. Mann, Thomas K. Hansen, Thomas Idorn et al. · The Lancet Diabetes & Endocrinology · 2020 · 149 citations

, , +17

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Vanita R. Aroda, Matthew Capehorn, Louis Chaykin et al. · Diabetes Obesity and Metabolism · 2019 · 28 citations · Full text

, , +17

Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials

Johan Jendle, Andreas L. Birkenfeld, William H. Polonsky et al. · Diabetes Obesity and Metabolism · 2019 · 19 citations · Full text

, , +17

1–5 of 5